Thanks, Great. it. Tom. Appreciate
opportunity Before healthcare. around I a a products and to Investor Day, of week specifics areas both our jump and purpose-driven I actions couldn't agenda to deliver with let broad around support includes I and we BD. portfolio healthcare and joining more solutions, we innovative BD in strategy long-term of our investment excited the outcomes sharing me with are delivery say our a the engaging world. community many the and important more in, healthcare have value. deep meaningful next tremendous impact growth leadership be is forward on to look pipeline taking has that company during shape our the positions, first make that and Combined a about
X.X% get basis, commitments future. we're XXXX, as let's of and XX basis. neutral comments, quarter our momentum that, enter well-positioned the Tom's Slide Echoing XXXX, strong increased on expectations. our reported And revenues ahead Fourth for our X.X% we a our on FX have billion with an results. $X.X into high-level So we're summarizes performance. of revenue and delivered on we in
against Our and including The testing, fluctuations. in breadth base by activity continued the portfolio, segments. all In improvement driven procedure diagnostic diversification QX, increased levels across total we higher COVID utilization three and revenues insulation X.X% performance and routine business healthcare saw BD and strong provides of overall acuity. lab COVID-driven testing
Interventional across year, X.X%, base fiscal our with X.X% testing, our XXXX, revenues the X.X% about in or momentum Life business COVID Compared of growth segment, full the demonstrates excluding revenues and X% in our or the X.X% strength the ship XX.X% regionally, China to in growth of hold. XX.X% the particularly Latin our the strategy base and and For segment. for when of grew also business America. which Sciences, Base business grew Medical the strong Alaris segments was U.S., fiscal adjusting in
by Medical products, U.S. in and the increased to prior-year our growing businesses. comparable quarter $X.X by to in billion devices. Systems and the needs. vascular high Turning Solutions revenues gains in XX.X% in our and number revenues revenues were pump for fourth Delivery strong hospital Medication to QX and Slide increased driven and MDS year acuity, of the last Pharmaceutical XX, delivered segment the demand X.X% in infusion led reflects core MMS, our Europe and catheters placements utilization Europe care competitive higher support despite In
for strongest our with than from in see of timing growth high Pharm see device benefited about QX is our by biologics, contracts. the a and growth of normalized slightly XX.X% continue to-date certain driven prefilled vial X.X% care for with quarters for we capacity dispensing a contracts market other Demand basis, the growth one prefilled devices platform strong committed being growth systems and solid committed of and On conversion demand diabetes diabetes associated reflects Revenue sales in aided drugs. expected devices enabled to prefilled continued growth better number demand. expansion. to fast-paced We and for by injectable of being our by flat. vaccines,
quarter $X.X Life billion Sciences Slide revenues the Turning fourth increasing X.X%. XX, in BD totaled to
lower were Early began our offset growth we $XXX believe XX% and enter testing variant, sales testing demand declining also microbiology, to Delta Solutions by both and the care and shipping business core pricing in in testing highest both base in strong improved, and assays, base as fluid care in by grew to million In the driven BD the assays XX.X%. patients. million of excluding of due of also utilization revenues. million QX. our quarterly during standard was and the IVD BD symptomatic products XX for Veritor become lab revenues up increased COVID by our base robust, reflects test normal across flu for research combination of which seeing growth Integrated included We're season. point in in MAX the laboratory QX $XXX about Despite over as IDS, XX.X% business is MAX used COVID IDS from and volume will partially lab However both increased utilization levels. COVID growth strong demand and Sciences sales that COVID Biosciences, year-over-year. shipping declined double-digit products combination of specimen testing XX.X% in COVID care driven Diagnostics market. Performance by Life testing, solutions, revenues is and Biosciences the revenues returning of we increased driven demand for tests, the to management
We research see for globally. reagents demand to solid continue
new launched vehicle well strong has for is e-commerce received recently Our with a growth and site traffic. been
Turning to the in quarter growing X.X%. Slide $X.X Interventional revenues BD billion totaled XX, nearly fourth
As communicated, procedures began variant U.S. previously elective see August. in on Delta July in we on we the to impact certain states and an
continuation that Peripheral and slightly reduced hospitals anticipated Intervention our some businesses While restricted it than in as we impact, and access surgery greater elective was procedures. contemplated of
as oncology ChloraPrep market and have saw continued capabilities Delta product. reflecting also XX.X%, recovery prevention force infection we in strength the of performance the and increased variant. Targeted impacts product elective in about recall strong Growth continues cancer Arctic RPI prevention procedures, PI driven with adoption platform. and Intervention is as some well biosurgery grew Partially growth remedy. We hernia Revenues to temporary despite supply atherectomy as of Sun of double-digit our completed the launched also now in demand business a surgery X.X%. Critical basis recently for points. leveraged Our as and infection Management Care in XXX impacted sterile X.X% offsetting continued continued sales an continued adoption our year-over-year reflects by in growth Temperature disruption this Peripheral which from acute with PureWick, a people by revenues grew within was screenings. Urology that be urology by strong more the growth impacted in
caught We of quarter FY to up be within XXXX. shipments the expect first
fiscal full UCC the For in grew year XXXX, X.X%.
P&L. XX, full-year to our and Slide Turning adjusted and QX
EPS and pricing the delivered business, increased $X.XX. declined diluted and $XXX of reinvestment higher a to we share primarily COVID slightly income count basis, as a quarter above in EPS neutral R&D less, million expectations, On testing-related share net currency costs well one-time net income net and the and declined costs of levels. as For adjusted with due EPS lower and reflecting by X.X% to our income repurchases. or X.X% shipping due lower inflation, testing
XX% Our the delivered revenue and line full-year we $XX.XX growth with and driven the EPS growth basis and QX adjusted net business. an neutral We FX the $X.X XX% operating previously with and of margin and full-year expectations company communicated were base margins expansion of over for by on billion operating income respectively, XXX in basis. strong points and for
operations to through XX% and fiscal investments BD has our cash XXXX increase in capital, us our R&D, in flow Slide an capital advance fiscal of billion support versus growth over in strategy to XXXX. This Turning from cash and allowed improvement $X.X XX, framework balanced totaled allocation M&A. flows XXXX, our
manufacturing in Tom invested lines mentioned. opportunities, to we the including previously support expenditures capital XXXX fiscal new During high-growth
In investing in advance strong will that to at and profile R&D M&A across addition million our over also support our we programs, businesses tucking in growth pipeline beyond. innovative X% $XXX invested of XXXX of in to sales our
We in in growth, dividends investments an with fiscal we leverage through repurchases. of year Beyond $X.X adjusted and $X.X the cash, returned to in capital ended billion ratio share shareholders times. in and billion billion net our $X X.X
I leverage allocation and position Investor upcoming And with Day. cash capital sharing to to value to look our you strategy create us current flexibility Our gives our multiple through forward about more levers.
Now turning on to guidance XX. our fiscal XXXX Slide
our that assumptions guidance support First range. the macro
of and we COVID-XX there While not stabilization of some to variability, are rates to expect we to be significant continue assuming be continued disruptions restrictions continue continued as will and to vaccination see procedures increase easing procedure recognize not will there volumes. assume
we anticipate constraints to while expect not to do worsening inflationary pressures. return Additionally, not levels, conditions macro or normal do supply chain we
assumed the impact not legislation any we would that impact Finally, have broader of changes market.
generated in testing we regarding preliminary score a provide you excluded Given XXXX, testing guidance from revenue base that margins with business only previously provided significant base relative to fiscal model this help our testing a year, along our performance, income and sales between and guidance COVID to underlying split through testing to continue our context business. base we will
So comments specific assumptions. a few on testing
of combination comparable $XX million. assumptions revenue include flu which a as level normal at of sales business million COVID should our flu base a assays Our season, to you to $XXX think
in significantly COVID only our assume XXXX. fiscal addition combo the is revenues, which to in we less test be business For demand base testing, would
Given current the around break largely our uncertainty variability in outbreaks, the the COVID environment on to of driven intensity confirmed orders. and based assumptions length by are
either profits period COVID to upside only income, manage as well We were incremental revenues create compensate be we to testing resulting our allowing and first million of flow substantially positions value further would through this any of used through. are or for procedure would be revenue $XXX base impacting uncertainty. reinvestment Any through softness which about testing to to revenue. higher, assuming If
Tom confident are resources that as and we've program. Alaris, were behind in we invested Regarding the making progress noted, the we this
our infusion would clearances are filing prudent particularly timelines. As and our not to what not not share we guidance include XXXX. shared we previously expect do with does inherently previously, be Consistent and a complex, clearance predict not we fiscal in XXX(k) pump so
will as year line shipments Capital Alaris But that XXXX. only necessity revenues assumed fiscal time we've with generally made out the difficult this how will Additionally, are at be in it process. is under things predict medical to of being play our
perspective some Let share underlying now guidance. me what on is base our
that productivity pipeline strategic further by in our acquisitions will increased be with our we've the across portfolio resulting R&D. for balanced and from well-positioned segments in added are robust enabled in growth innovation to three strong are Growth We categories. positioned high-growth investments a
settings. guidance While we above in with enabling base tools, Medical relative aren't companion laboratory of accretive Interventional company Improving the total smart, segment to Sciences inline, the higher-growth total segment slightly care chronic care as Life are investments strategy growth growth. with expect increased below, from both high-growth In to Interventional to its base be growth, inorganic, company be to our growth in space. research in to BD slightly providing spaces. segment, be alternative specific Medical treatment we do and and continuing we evolving by leadership assays, gains spaces differentiated with categories is peripheral labeling include smart competitive automated care disease continued diagnostics Sciences catheters market such workflows prefilled non-acute chronic diagnostics, new healthcare while growing in leadership while disease as solutions category expect expanded and through categories leadership to solutions and treatment, position care in our and care extend COR. of is positions holds These reagents and significant attractive Life and investing investments migrating and in in continuing devices, invest connected we such in point to and clinically to product above research continuing growth settings. offerings, transforming investing product where organic
of examples BDI Straub strategy. Medical for growth and we Our our driving acquisition are of line are PureWay good product how
to XXXX. billion grow to XX fiscal an to on Slide basis, base X% our to compared neutral in expect FX fiscal Turning XXXX, X% and $XX.X for revenues guidance we
XX $XXX All-in rates are currency, we to expect illustrative only company testing total purposes, in Based $XX.X revenues. testing, and the in plus billion about for points, For $XXX in approximately COVID fiscal be revenues spot million assuming illustrative on to would basis million of only reported of XXXX. the currency revenue. billion we base headwind a range COVID $XX.X current or
to Due our approximately We fiscal business margin XX.X%. operating operating margins items additional our testing to above points in improve over to the levels, modestly operating COVID only base on for XXX margin few models. base business basis your we test margins. XXXX current COVID base of pricing be expect A expect
$XX interest/other the giving activities million We fiscal in of we refinancing XXXX. expect up in to improvement quarter in fourth completed debt
is items we count, compensation you're SSG&A. increasing given a expect be an also M&A, for As to rate repeat. And share fluctuate XX.X% repurchases in tax while terms of tax to part deferred due aware, in effective value creation. offset to priority in XXXX of which remains of XX.X% share interest/other consistent will We not discrete can tuck-in plan
In $XX.XX addition our to quarter EPS expect adjusted floor testing year-over-year minimum our All-in, we repurchases outstanding shares we benefit with share million; dilution fiscal XXXX in COVID $XX.XX, at share the $XXX from in offset assumes from share-based were to that ending guidance any completed our repurchases $XX compensation. provided excluding between earnings above be on the and well EPS only being call. August, third where
are in by key some today. take have will programs, addressed new a everyone initiatives reground we pursuing. few a that naturally considerations we on There are resulted Turning existing pressure, improvement others some of to which me margin through be improvements are minute Slide XX, and regarding restored, be where first to let further margin with margins, will that
the XXXX, for our investments total over XXXX. other creating and we the programs. COVID-XX basis XX.X% of benefited by versus accelerate In profile points improve margin margin margin testing full-year made from operating total Our did net to value of XXX growth
which of look XX.X%, neutral it's margins improved So at an best versus testing XXXX. on excluding base basis COVID-XX our also operating FX to
negative related the our along by primarily negatively margin factors: hold, inflation utilization, Alaris However, key they under normal in lag with Each by COGS items do and levels and XXX ship these COVID-XX shipping, pre-pandemic was impacted impacted points, of They a volume decision above each. four basis levels. margin operating basis remaining base to headwinds. the about as of R&D including The pre-pandemic collectively sales XX to competitive investments X% strategically erosion by levels at about increase XX% impact growth. items few points and support driven was from small for averaged of accounted about to long-term more a currency
anticipate in the basis XXX driven I XXXX shared, by by fiscal around improving base following. operating As points margins we
COVID-XX fully in volumes from and our be XXXX. as will plans. XXXX in impacts These First, given like margin about base XXXX underutilization more will increased operating improvement but experienced fiscal XXX short-term associated than drive all such and basis carried fiscal impacts into sales momentum, restored versus companies in our we strong points
to impact our current footprint, and margins. and also impact spot our recapture inventory timing fluctuations XX currency expect of normal points network to distribution our Based given currency with P&L the in headwind our FX XXXX. our outlook, the in operating the about face basis along on movements rates inventory Second, of can reported manufacturing we margin translation; we we global throughout of
Lastly, we realized in increased XXXX pressures outbound be best-in-class intend unprecedented how labor fiscal to environment. XXXX, carry in driven and pressures we navigate transportation will we into this inflationary fiscal by inbound and These costs. resin, and inflationary
our air are through actions include initiatives. project simplification control. expanding across intend and and and Recode as improvements spend to These freight margin efforts; such procurement drive additional as We existing cost reduced new shipping such optimization supplier
we In implemented. And offset this addition, these continuous know, environment, are actions, pressures invest in in already to pricing in plants. our improvement which we to need we have actions behind inevitably, through being place
inflation impact in are our focused to In R&D. competitive are XXXX. also normal operating we XXXX, from while above forecasting levels leveraging investments SSG&A margin from on maintaining additional investments, We
on being margin year of drive points a margin with the to-date additional play Combined reversing restoring pressure margin than already key inflationary improvement. in incremental an are offset to made initiatives we've XX points to utilization, drive significant anticipate mitigate to gross a base we pressure inflationary that basis pressures our around operating and this However, a we part progress FX Increased levels. also will improvement. initiatives basis to more XXX expect these pre-pandemic to underway, able
committed are to compensation year's improvement the performance and for in key plan against margin We will measurement goals be delivering this a across company. thus these
Our exceeding will a margin fiscal which longer sharing week Investor fiscal our pre-pandemic more significant XXXX in pre-pandemic operating recovery at initiatives improvement XXXX. includes margin be levels. margin forward look step to about next our We towards recovery Day, of term levels
Slide Turning to XX.
on growth operational testing just and above driven net EPS Our only the growth our August expect of by we we margin the guidance year-over-year in profit as we fiscal reflects COVID base provided $XX EPS reinvestment. discussed, revenue XXXX well adjusted our strong call. business, In improvement, with decline
Slide turning Now XX.
fiscal guidance diabetes includes Our business. also our XXXX
shareholders to We continue creating well-positioned success. both significant for our and NewCo value spin-off a opportunity is RemainCo believe and are for the
this reinforce items all moment Let compelling stakeholders. to some to me make key take to a
be intended the Diabetes pure-play receive will the and unit. later to diabetes cash the proceeds effective to focus largest cash to intended growth. as diabetes to to the use normal spins, allocate with plan be of spin cash today, We efficiently and drive equivalent NewCo more its flow existence tax in discontinued and effectively related higher for free its strategic capital to distribution drive operation. multiple And companies margins one ability strong the goals, an and for generated RemainCo tax business diabetes by Carve-out is us EPS corporate to date enhances financials classify Care be financials years more spin purposes. revenue Form plan growth restate of income a The and to is our federal a is provide the are slower at spin's proposed declining. The a expected than details revenue date. with profile, course growth as after the is its we average on to XX. available will cares RemainCo's as
expect lower after but profile as one sales they're Diabetes margins higher Given percent of the with restated higher a of Care rate the growth. a to margin business, should of RemainCo's be
this creating transition establishing a making successful ahead costs. services opportunity that We cited and and are for for all. stranded remaining will We value what's agreement offset for NewCo
Now turning XX. Slide to
phasing to to Finally, wanted for considerations moment I some share your models. take a
First, the in quarters expect comp in XXXX, be higher the QX resulting to from growth resurgence across due exception we QX, FY to where the normalized COVID of growth primarily Interventional. easier with expect revenue we
In addition, towards we expect weighted half COVID testing of revenue to be the year. first the
flow lower inventory. initiatives of Second, we margin be XXXX the on they earlier and be in the benefit have improvement given in half increased through began as inflation expect fiscal gross we to that will a first initiated lag cost
the prominent year. inventory and of expect inflation be improve through flow the across We most balance QX the in to to
FY as rate in range our expense around and dollars the items. jurisdictional anticipate for full-year, variability, our SSG&A for tax certain COVID we of by expect to potential assumptions fairly we XX.X% quarter. Third, past includes XX.X%. rate be rateable discrete to of effective mix and XXXX, move Fourth, we to R&D This be income
our summary, lower discrete key in In of realization of XXXX potentially our could against strategic in quarter-to-quarter, was result items timing the fiscal a course, significant by range. including Of rate variability marked priorities. QX a and year progress execution
growth, business, momentum, well-positioned innovation investments in our meaningful improvement. to reflected initiatives and and progress look for and as sheet flow our in our XXXX in base cash we excellent pipeline, strong executing momentum with increased forward, visibility tuck-in M&A we margin our guidance, balance clear are As
share We our with excited to Day. Investor at are outlook long-term our you
Nadia portion to Let turn call. of Q&A me back lead it now the to the
